SCHEMBL3515950

SCHEMBL3515950

C[Si](C)(C)CCOCn1nc(-c2ccncc2)c2cc([N+](=O)[O-])ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
CNR2 P34972 6/20 0.41
CNR1 P21554 5/20 0.41
ACHE P22303 4/20 0.41
PTPN11 Q06124 1/20 0.36
MAPT P10636 2/20 0.36
CYP19A1 P11511 3/20 0.36
CYP11B1 P15538 3/20 0.36
CYP11B2 P19099 3/20 0.36
F2RL3 Q96RI0 2/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
NPC1 O15118 2/20 0.35
PKN1 Q16512 1/20 0.35
PKN2 Q16513 1/20 0.35
SRC P12931 1/20 0.35
BRAF P15056 1/20 0.35
KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3704193 0.92 L3MBTL1 (0.39) L3MBTL1CNR2CNR1ACHEPTPN11
SCHEMBL5518753 0.91 L3MBTL1 (0.58) L3MBTL1CNR2CNR1ACHEMAPT
SCHEMBL16014237 0.88 L3MBTL1 (0.41) L3MBTL1CNR2CNR1ACHEMAPT
SCHEMBL22445949 0.84 CNR2 (0.42) L3MBTL1CNR2CNR1ACHEMAPT
SCHEMBL23782982 0.83 CNR2 (0.40) L3MBTL1CNR2CNR1ACHEMAPT
SCHEMBL27596540 0.83 CNR2 (0.40) L3MBTL1CNR2CNR1ACHEMAPT
SCHEMBL3517141 0.82 CNR2 (0.45) L3MBTL1CNR2CNR1ACHEMAPT
SCHEMBL30183407 0.82 CNR2 (0.45) L3MBTL1CNR2CNR1ACHEMAPT
SCHEMBL24809118 0.82 DGAT1 (0.40) MAPTNPC1
SCHEMBL3515565 0.82 NPC1 (0.34) CNR2CNR1ACHEMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022271840-A1 SELECTIVE INDAZOLE LRRK2 INHIBITORS AND METHODS FOR USE THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-12-29 WO disclosed
US-20100298377-A1 NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2010-11-25 US disclosed
EP-2170865-A2 NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS Sanofi-Aventis (FR) 2010-04-07 EP disclosed
WO-2009010660-A2 SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298377-A1 NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS WEE1, PRMT1, ABL1 L3MBTL1 2648/4885CNR2 493/4885CNR1 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.